# The added value of echocardiography in hypertensive heart disease

Fausto J. Pinto, MD, PhD, FESC, FACC, FASE, FSCAI



Faculdade de Medicina Universidade de Lisboa



האיגוד הקרדיולוגי בישראל האיגוד הישראלי לכירורגית לב וחזה ISRAEL SOCIETY OF CARDIOTHORACIC SURGERY ISRAEL HEART SOCIETY





The 60<sup>th</sup> International Conference of the Israel Heart Society in association with the Israel Society of Cardiothoracic Surgery

22-23 April 2013, ICC International Convention Center, Jerusalem





Faculdade de Medicina Universidade de Lisboa





ESC Guidelines for the Diagnosis and Treatment of CHF - 2005 13





#### Diastolic dysfunction or Preserved Left Ventricular Ejection Fraction (PLVEF)

 Diastolic heart failure is often presumed to be present when symptoms and signs of heart failure occur in the presence of a PLVEF (normal ejection fraction/normal end-diastolic volume) at rest.

Predominant diastolic dysfunction is relatively uncommon in younger patients but increases in importance in the elderly, in particular women, in whom systolic hypertension and myocardial hypertrophy with fibrosis are contributors to cardiac dysfunction.

ESC Guidelines for the Diagnosis and Treatment of CHF - 2005 10











#### Progressive increase in cardiovascular morbidity (left) and all-cause mortality (right) rates from first to fifth quintile of distribution of LV mass index



Schillaci, G. et al. Hypertension 2000;35:580-589

#### Cumulative survival by quintile of LV mass index





Schillaci, G. et al. Hypertension 2000;35:580-589

# Left ventricular geometry at baseline and after 4.8 years antihypertensive treatment. (LIFE Trial)





#### Diastolic Dysfunction: Hypertension

Ischemia Impaired Ca<sup>++</sup> handling LV relaxation Small end systolic volume LV stiffness LV hypertrophy **Myocardial fibrosis** 



### **Diastolic function and Hypertension**





Borges, M. C. C. et al. Hypertension 2006;47:854-860

#### **Diastolic function in Hypertension**



fjp



### **Systolic function and Hypertension**





Borges, M. C. C. et al. Hypertension 2006;47:854-8

# Tissue Tracking and LV systolic function in HTN





Poulsen SH et al J Am Soc Echocardiog 2003;16:724

# **Tissue Tracking Score Index**

LV Mass Index vs Tissue Tracking wall score index





Poulsen SH et al J Am Soc Echocardiog 2003;16:724

fjp

# Mitral Ring Displacement in HTN

Table 4 Longitudinal HTN and NTN	mitral ring d	isplacement in
	HNT	NTN
Septum (mm) Anterior wall (mm) Lateral wall (mm) Inferior wall (mm) Average over the four walls (mm)	$\begin{array}{c} 10.1 \pm 0.2^{\dagger} \\ 11.2 \pm 0.3^{\dagger} \\ 13.8 \pm 0.4 \\ 12.7 \pm 0.3^{\ast} \\ 12.0 \pm 0.3^{\dagger} \end{array}$	$\begin{array}{c} 13.0\pm 0.3\\ 13.5\pm 0.4\\ 14.8\pm 0.4\\ 14.4\pm 0.5\\ 13.9\pm 0.3\end{array}$
* $p < 0.005$ and * $p < 0.0001$ .		



Baltabaeva A et al Eur J Echocardiogr 200 **fjp** 

# Longitudinal Septal displacement and MAP





Baltabaeva A et al Eur J Echocardiogr 200 **fjp** 

## Patterns of Hypertensive Heart



# Septal velocities, S/SR HTN Non HTN



Baltabaeva A et al Eur J Echocardiogr 200 **fjp** 



Graph representing the parallel changes in mean Ea, longitudinal strain, as well as filling pressures, wall thickness and number of segments with altered relaxation pattern-Segmental





#### Relation of abnormal segmental relaxation and annular septal Ea. Blood pool indices (upper





## Hypertensive Heart Disease



Sousa C, Gonçalves S, Pinto FJ Rev Port Cardiol 2010;29:49





	Control	HTN	р
GS (%)	-19,98 <u>+</u> 2,17	-18,28 <u>+</u> 3,09	p = 0,015*
GSRs (1/sec)	-1,03 <u>+</u> 0,14	-0,94 <u>+</u> 0,19	p = 0,021*
GSRe (1/sec)	1,43 <u>+</u> 0,33	1,03 <u>+</u> 0,28	p <0,001*
GSRa (1/sec)	0,89 <u>+</u> 0,19	0,94 <u>+</u> 0,27	p = 0,234



Gonçalves S, Pinto FJ ESC 2009 fjp

LV longitudinal and radial function in essential hypertension

- N=81 pts
- LV longitudinal systolic fx and radial deformation (strain-sE, SR, postsystolic strain psE)

sE (%)	Controls	NYHA I	NYHA II	NYHA III	NYHA IV
Septal basal	17,5+/-2,9	12,4+/-5,1*	12,2+/-4,8*	11,1+/-4,1*	4,3+/-3,8*§
Septal mid-api	20,7+/-4,8	20,6+/-4,1	20,7+/-3,3	17,1+/-4,2*.	7,4+/-4,7*§
Lateral basal	21,1+/-3,7	21,1+/-3,6	16,4+/-4,1*.	15,6+/-4,8*.	6,7+/-4,4*§
Lateral mid-api	22,06+/-2,9	20,5+/ 3,9	19,8+/-2,7	17,3+/-4,4*.	10,7+/-3,9*§
Posterior basal	39,7+/-11,6	50,8+/-12,7*	39,7+/-15,5.	37,2+/-13,2.	16,3+/-9,1*§

p<0.05: \* - vs controls; § - vs NYHA I, II and III;  $\neq$  - vs NYHA I; + - vs NYHA I and II



Plaksej R et al. EUROECHO 2007

LV longitudinal and radial function in essential hypertension

- In hypertensive pts:
  - –LV longitudinal fx progressively deteriorates from NYHA cl I to IV
  - -LV radial fx enhances in the early phase (compensatory response?) and then declines



Relationships between severity of diastolic dysfunction (DD) (left) and left atrial (LA) volume index (right) and survival



#### LA strain curves obtained from the apical fourchamber view in four example patients





#### LA strain indexes in the four study groups.



\*P<.05 vs Controls <sup>†</sup>P<.05 vs Hypertensives and vs Diabetics <sup>‡</sup>P<.05 vs Hypertensives



#### The importance of RV function





### RV Dysfunction as a predictor of mortality in heart failure



Kjaergaard J et al Eur J Heart Failure 2007;9:610



# Tricuspid annular velocities/motion

	Systolic Velocity (s - cm/s)	Early Diastolic velocity (e' - cm/s)	Late diastolic velocity (a' - cm/s)	Tricuspid Annular motion (mm)
Group A (n=28)	19.3 +/- 4.5	16.3 +/- 3.4	13.2 +/- 3.9	29.6 +/- 5.5
Group B (n=31)	12.3 +/- 3.1	9.12+/- 3.0	13.9 +/- 4.7	24.4+/- 8.9
p	<0.01	<0.01	ns	<0.05



Peak systolic strain (peak ε, top left panel), and systolic (SSR, bottom left panel) and diastolic (early, ESR, top right panel, and late, ASR, bottom right panel) strain rate by ascending 24 h systolic blood pressure tertiles (n = 29, 30, and 30, respectively, cut-offs: 117 and 130 mmHg).





### Assessment of RV/LV Function in Hypertension

- Early impairment of systolic and diastolic function can be detected by tissue velocities and myocardial deformation parameters at early stages in hypertensive pts.
- RV assessment as a risk marker for HTN?
- Monitoring therapeutic interventions?



#### Echocardiography in HTN









. . .

www.escardio.org

